Tirzepatide May Show Kidney Benefits in Diabetes Patients
New research links specific protein levels to improved kidney function outcomes in patients with diabetes.
Updated on Oct. 20, 2026 in Diabetes
Live Poll
Would you trust personalized medical testing to determine which prescription drugs are most effective for you?
A new analysis of 220 patients with type 2 diabetes and stage 3 chronic kidney disease indicates that the drug tirzepatide may help reduce the risk of rapid kidney function decline. The findings, which compare responses based on specific protein levels, could eventually help doctors identify which patients might benefit most from the treatment.
Why it matters
Managing kidney health is a priority for those with diabetes, and identifying biological markers that predict treatment success could lead to more personalized care. This study highlights how certain plasma proteins may influence how well the body responds to specific medical interventions for kidney preservation.
In a 24-month study of 220 patients with type 2 diabetes and stage 3 chronic kidney disease, researchers compared tirzepatide to insulin glargine. The results showed that 5% of tirzepatide recipients experienced rapid kidney decline compared to 13% of those on insulin.
The players
Tirzepatide
A medication approved for the treatment of type 2 diabetes and weight management.
Insulin glargine
A long-acting insulin used to help manage blood sugar levels in patients with diabetes.
The details
Researchers utilized the Joslin Kidney Panel to measure baseline concentrations of 21 proteins to see if they correlated with different treatment outcomes. They found that treatment response varied significantly across protein concentration tertiles. Specifically, among patients with the highest levels of the protein TNF-R10B, those taking tirzepatide had an 8.3% rate of rapid kidney decline, while those on insulin glargine had a 32.4% rate.
Timeline
24 months was the mean follow-up period for the study participants.
October 2026 was when the analysis was presented at ASN Kidney Week 2026.
Health Landscape
This research builds on the ongoing use of the Joslin Kidney Panel to better understand kidney disease progression in diabetic populations. It represents an evolving effort to move beyond one-size-fits-all diabetes care by identifying biological predictors of treatment efficacy.
If you are managing type 2 diabetes and chronic kidney disease, these findings highlight the importance of monitoring kidney function markers with your healthcare team. Discussing current treatment options and long-term renal health goals with your physician remains the best approach to personalized care.
The takeaway
This analysis suggests that specific protein levels might help predict who benefits most from kidney-protective therapies for diabetes. Continue to track your kidney function tests closely and consult your doctor to determine the most effective treatment plan for your specific health needs.
Further reading
Learn more about the latest research and management strategies in our Diabetes section.
Live Poll
Would you trust personalized medical testing to determine which prescription drugs are most effective for you?
